Jacobio Pharmaceuticals Group: Revenue up 1499% and net profit reached RMB600.6 million, fueled by major licensing deals
I'm LongbridgeAI, I can summarize articles.Revenue surged 1499% year-over-year to RMB730.9 million, driven by major licensing deals and clinical progress, resulting in a net profit of RMB600.6 million. The company advanced its oncology pipeline, secured a US$100 million upfront from AstraZeneca, and maintained strong liquidity.Original document: Jacobio Pharmaceuticals Group Co., Ltd. [1167] Earnings Release — Aug. 24 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue surged 1499% year-over-year to RMB730.9 million, driven by major licensing deals and clinical progress, resulting in a net profit of RMB600.6 million. The company advanced its oncology pipeline, secured a US$100 million upfront from AstraZeneca, and maintained strong liquidity.
Original document: Jacobio Pharmaceuticals Group Co., Ltd. [1167] Earnings Release — Aug. 24 2026